CAS
SRPT icon

Coppell Advisory Solutions’s Sarepta Therapeutics SRPT Stock Holding History

Coppell Advisory Solutions’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2
Closed -$242 – 1655
2024
Q4 		$242 Hold
2
– – ﹤0.01% 1814
2024
Q3 		$249 Hold
2
– – ﹤0.01% 1711
2024
Q2 		$316 Buy
+2
New +$257 ﹤0.01% 1622
2023
Q4 		$21.4K Buy
+222
New +$21.3K ﹤0.01% 715

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Coppell Advisory Solutions's SRPT Position: Q1 2025 in Review

Coppell Advisory Solutions sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 2 shares — an estimated $242 sold.

Coppell Advisory Solutions first reported a position in SRPT in Q4 2023 and held it in 4 quarters. The position peaked at $21.4K in Q4 2023. 430 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

  • Coppell Advisory Solutions reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Coppell Advisory Solutions sold 2 Sarepta Therapeutics shares in Q1 2025, an estimated $242.
  • Coppell Advisory Solutions first reported a position in Sarepta Therapeutics in Q4 2023 and held it in 4 quarters.
  • Coppell Advisory Solutions's Sarepta Therapeutics position peaked at $21.4K in Q4 2023.
  • 430 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on Coppell Advisory Solutions's 13F filing for Q1 2025, filed 16 May 2025.